25 Years of the WHO essential medicines lists: Progress and challenges

Lancet

Volumn 361, Issue 9370, 2003, Pages 1723-1729

  Laing, Richard ^a   Waning, Brenda ^b   Gray, Andy ^c   Ford, Nathan ^d   'T Hoen, Ellen ^d  

^a BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^b MA Coll of Pharm and Hlth Sci   (United States)

^c UNIVERSITY OF KWAZULU NATAL   (South Africa)

^d MÉDECINS SANS FRONTIÈRES   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ESSENTIAL DRUG;

COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG INFORMATION; DRUG MARKETING; DRUG SAFETY; EXPERIENCE; HEALTH CARE ORGANIZATION; HUMAN; MORBIDITY; PATENT; PRESCRIPTION; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; SOUTH AFRICA; WORLD HEALTH ORGANIZATION;

EID: 0038324475     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)13375-2     Document Type: Review

References (55)

1. Executive Board WHO. Revised procedures for updating the WHO model list of essential drugs: a summary of proposals and processes. EB108/INF.DOC./2. Geneva: World Health Organization, 2001.
2. WHO. The selection of essential drugs: report of a WHO expert committee. (Tech Rep Ser WHO no 615). Geneva: World Health Organization, 1977.
3. The world drug situation. 1988;World Health Organization, Geneva.
4. Howard N.J., Laing R.O. Changes in the World Health Organization essential drug list. Lancet. 338:1991;743-745.
5. Resolution WHA28.66. 1975;World Health Organization, Geneva.
6. WHO/UNICEF. Primary health care: report of the International Conference on Primary Health Care, Alma-Alta, USSR, Sept 6-12, 1978. Health for all, series 1. Geneva: World Health Organization, 1978.
7. Kanji N., Hardon A., Harnmeijer J.W., Mamdani M., Walt G. Drugs policy in developing countries. 1992;Zed Books, London.
8. Quick J.D., Rankin J.R., Laing R.O., et al. Managing drug supply: the selection, procurement, distribution and use of pharmaceuticals. 2nd edn: 1997;Kumarian Press, West Hartford.
9. The rational use of drugs: report. 1987;World Health Organization, Geneva.
10. Hogerzeil HV. Selection of essential drugs: standardized supply of essential drugs in Ghana, 1. Tropical Doctor 1984; 16: 1986: 113-116.
11. Quick J.D. Managing drug supply. 1981;Management Sciences for Health, Boston.
12. The use of essential drugs: report of a WHO expert committee. Technical report series no 895. 2000;World Health Organization, Geneva.
13. 't Hoen E. TRIPS, pharmaceutical patents and access to essential medicines: a long way from Seattle to Doha. Chic J Int Law. 1:2002;27-50.
14. Updating and disseminating the WHO Model List of Essential Drugs: the way forward. 2001;World Health Organization, Geneva.
15. Steiger W. Comments on the recommendations contained in the WHO discussion document "Updating and Disseminating the World Health Organization Model List of Essential Drugs: The Way Forward" 2001;Department of Health and Human Services, Washington.
16. Procedure to update and disseminate the WHO model list of essential medicines document EB109/8 (Annex). 2002;World Health Organization, Geneva.
17. WHO. The use of essential drugs: report of a WHO expert committee. Tech Rep Ser WHO no 914. Geneva: World Health Organization, 2002. http://www.who.int/medicines/organization/par/edl/report2002-vers 14.doc (accessed Dec 10, 2002).
18. WHO. Website for alphabetical, ATC and translated lists. http://www.who.int/medicines/organization/par/edl/eml.shtml (accessed Dec 10, 2002).
19. Report on the 12th Expert Committee on the Selection and Use of Essential Medicines. 2002;World Health Organization, Geneva.
20. Selection of essential drugs. Tech Rep Ser WHO no 641. 1979;World Health Organization, Geneva.
21. WHO. The use of essential drugs - model list of essential drugs (fifth list). Tech Rep Ser WHO no 770. Geneva: World Health Organization, 1988.
22. WHO. The use of essential drugs: model list of essential drugs (ninth list). Tech Rep Ser WHO no 867. Geneva: World Health Organization, 1997.
23. WHO. Practical chemotherapy of malaria. Tech Rep Ser WHO no 805. Geneva: World Health Organization, 1990.
24. WHO. Management of uncomplicated malaria and the use of antimalarial drugs for the protection of travellers: report of an informal consultation, Geneva, Sept 18-21, 1995. WHO/MAL/96.1075 Rev 1. Geneva: World Health Organization, 1997.
25. WHO. Antimalarial drug combination therapy, report of a WHO technical consultation, April 4-5, 2001. WHO/CDS/RBM/2001.35. Geneva: World Health Organization, 2001.
26. Department of Health South Africa. National drug policy for South Africa. Pretoria: Department of Health, 1996. http://www.sadap.org.za/ndp (accessed Dec 10, 2002).
27. Gray A., Eagles P. Drug policy. Barron P. South African health review 1997. 1997;99-104 Health Systems Trust, Durban.
28. Gray A., Suleman F. Drug policy. Crisp N., Ntuli A. South African health review 1999. 1999;161-174 Health Systems Trust, Durban.
29. Department of Health South Africa. Policy guideline for management of transmission of human immunodeficiency virus (HIV) and sexually transmitted infections in sexual assault. http://www.doh.gov.za/docs/factsheets/guidelines/rape-f.html (accessed Dec 10, 2002).
30. Gray A, Matsebula T, Blaauw D, Schneider H, Gilson L. Policy change in a context of transition: drug policy in South Africa 1989-1999. Centre for Health Policy, University of the Witwatersrand. http://www.hst.org.za/chp/pubs/policy.pdf (accessed Dec 10, 2002).
31. Chetley A. A healthy business? World health and the pharmaceutical industry. 1990;75 Zed Books, London.
32. International Federation of Pharmaceutical Manufacturers Association. Issue paper: the "Essential Drugs" concept - February, 1997. http://www.pharmweb.net/pwmirror/pw9/ifpma/pdfifpma/edl.pdf (accessed Oct 16, 2002).
33. Anon. Essential drug list in Italy. Scrip 1987; November 11, No 1, 256: 1.
34. 't Hoen E., Hodgkin C. Harmful human use of donated veterinary drug. Lancet. 342:1993;308-309.
35. Humanitarian agency's essential drugs policy. WHO Essen Drugs Mon 2001; no 30: 23.
36. Maritoux J., Pinel J. Essential drugs: practical guidelines intended for physicians, pharmacists, nurses and medical auxillaries. 3rd edn: 2002;Médecins Sans Frontières, Paris.
37. Anon. Developing essential drugs policies: a guide for NGOs. Amsterdam: Health Action International (HAI)-Europe in collaboration with an international NGO working group, 1998.
38. WHO revised drug strategy. World Health Assembly resolution WHA39.27. 1986;World Health Organization, Geneva.
39. World Health Assembly resolution WHA resolution 54.11. 2001;World Health Organization, Geneva.
40. Revised drug strategy. World Health Assembly resolution WHA 49.14. 1996;World Health Organization, Geneva.
41. Velasquez G., Boulet P. Globalization and access to drugs: perspectives on the WTO/TRIPS agreement. 2nd edn: 1999;World Health Organization, Geneva.
42. Anon. European Commission (DG1), note on the WHO's revised drug strategy, doc no 1/D/3/BW D (98). Brussels: European Commission, 1998. http://www.cptech.org/ip/health/who/eurds98.html (accessed Mar 24, 2002).
43. ds D.S. WHO. Scaling up the response to HIV/AIDS, World Health Assembly Resolution WHA 54.10 (2001). 2001;World Health Organization, WHO Medicines Strategy, World Health Assembly, Geneva.
44. WHO. Technical cooperation activities: information from other intergovernmental organizations, WHO doc no IP/C/W/305/Add.3. Geneva: World Health Organization, 2001.
45. Anon. WT/GC/W/282. Preparations for the 1999 ministerial conference: proposals regarding the TRIPS agreement. Communication from Venezuala, 1999. http://docsonline.wto.org/gen_search.asp (accessed May, 2003).
46. Anon. Common working paper of the EC, Hungary, Japan, Korea, Switzerland, and Turkey to the Seattle ministerial declaration 3, Nov 29, 1999. http://europa.eu.int/comm/trade/2000_round/friends.pdf (accessed Dec 10, 2002).
47. Scholtz M. Views and perspectives on compulsory licensing. Conference on AIDS and essential medicines and compulsory licensing, Geneva, March 27-29, 1999. Geneva: Médecins Sans Frontières, 1999.
48. World Trade Organization. Doha ministerial declaration on the TRIPS agreement and public health, paragraph 4, WTO doc no WT/MIN(01)/DEC/2 (2001). Qatar: World Trade Organization, 2001.
49. Editorial. Whose interests does the World Trade Organization serve? Lancet 2003; 361: 269.
50. WHO Medicines Strategy 2000-2003. 2000;World Health Organization, Geneva.
51. WHO. WHO model formulary. Geneva: World Health Organization, 2002. http://www.who.int/medicines/organization/par/formulary.shtml (accessed Dec 10, 2002).
52. WHO. Drug price information services: what is WHO doing to improve drug price information? WHO fact sheet. Geneva: World Health Organization, 2002. http://www.who.int/medicines/organization/par/ipc/drugpriceinfo.s html (accessed Dec 10, 2002).
53. WHO. WHO Child and Adolescent Health and Development, news and events: May-October 2002. http://www.who.int/child-adolescent-health/NEWS/news_7.htm (accessed Dec 10, 2002).
54. WHO. Statement by representative of WHO at WTO Council for TRIPS, Sept 17, 2002. http://www.who.int/mediacentre/trips/en (accessed Dec 10, 2002).
55. Trouiller P., Olliaro P., Torreele E., Orbinski J., Laing R., Ford N. Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet. 359:2002;2188-2194.